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Here, the streptavidin–biotin technology was applied to enable
organocatalytic transfer hydrogenation. By introducing a biotin-
tethered pyrrolidine (1) to the tetrameric streptavidin (T-Sav), the
resulting hybrid catalyst was able to mediate hydride transfer from
dihydro-benzylnicotinamide (BNAH) to a,b-unsaturated aldehydes.
Hydrogenation of cinnamaldehyde and some of its aryl-substituted
analogues was found to be nearly quantitative. Kinetic measure-
ments revealed that the T-Sav:1 assembly possesses enzyme-like
behavior, whereas isotope effect analysis, performed by QM/MM
simulations, illustrated that the step of hydride transfer is at least
partially rate-limiting. These results have proven the concept that
T-Sav can be used to host secondary amine-catalyzed transfer
hydrogenations.
In biological systems, nicotinamide is frequently used in the
transfer of electrons and hydrogen atoms1,2 and is typically found
in the form of NAD(P)H attached to an adenosine dinucleotide
appendix.3 While the adenosine dinucleotide motif is crucial for
molecular recognition and metabolic regulation in cells,4 this
appendix is a large and complex molecular burden that needs to
be addressed when it comes to synthetic applications.5 Conse-
quently, various cofactor recycling systems have been designed.6,7
In an alternative and potentially simpler approach, small organic
molecules can be used as hydride donors,8,9 such as the Hantzsch
ester,10 dihydro-benzylnicotinamide (BNAH) and their deri-
vatives.11,12 Nevertheless, there are only a handful of protein-
based catalysts reported to use simple hydride donors for reac-
tions, including ene-reductases (ERs),6,13 salicylate (SalH),
para-hydroxybenzoate (PHBH) and hydroxybenzoate (3HB6H)
hydroxylases,14 cytochrome P450,15 2-hydroxybiphenyl 3-monooxy-
genase (HbpA),16 Old Yellow Enzyme (TsOYE),17 and glucose dehy-
drogenases (GDH).18 Here, we aim to expand this collection by
proving the concept that organocatalytic artificial enzymes can
catalyze transfer hydrogenation using BNAH as a hydride source.19
Artificial enzymes can be created by docking chemical
catalysts into a designated protein scaffold, and the resulting
complex can potentially use hydride donors for reactions.7
Different approaches such as computational design, genetic
code expansion, supramolecular approaches and amino acid
modification have been used to accommodate chemical cata-
lytic systems for bioorthogonal reactions.19–25 Previously, the
streptavidin–biotin technology has been applied to host Ru and
Ir-mediated transfer hydrogenation with the use of NAD(P)H
and formic acid as hydride donors.7,26–28 Recently, streptavidin
has also been used to host organocatalysis, including secondary
amine, anion–p and DMAP catalysis;19,20,23,29,30 however,
the reaction profile of these organocatalytic systems remains
largely unexplored, and their possibility of mediating organo-
catalytic transfer hydrogenation reaction has not been tested.
Here, we demonstrate that secondary amine hosted by
streptavidin can be used to catalyze transfer hydrogenation
reactions (Fig. 1). Hybrid catalysts have been created by introducing
biotinylated secondary amines (1 and 2) to the tetrameric strep-
tavidin (T-Sav) or the monomeric counterpart (M-Sav). Upon
optimization, conversion of cinnamaldehyde (3) to its reduced
counterpart (5) was found to be 490% (Table 1). This work lays
the basis for enabling organocatalytic transfer hydrogenation in
biological contexts.
In previous studies, we have demonstrated that biotinylated
catalysts (1 and 2) were able to mediate Michael addition and
aldol condensation when introduced to the tetrameric strep-
tavidin (T-Sav).31 In this work, the reduction of cinnamaldehyde
3 by dihydrobenzyl nicotinamide (BNAH, 4) in KPi buffer
(10 mM, 10% methanol, pH 7.0) at room temperature serves
as the model transfer hydrogenation reaction and was assessed
by 1H NMR spectroscopy (Table 1). In the absence of protein or
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catalysts, only 3% of dihydrogenated product was observed
after 24 hour incubation when two equivalents of BNAH were
used (entry 1). Similarly, T-Sav (and its monomeric counterpart
M-Sav32,33) has negligible effects in catalyzing hydride transfer
(entries 2 and 3). When 1 mol% of catalyst 1 or 2 is used, the
estimated reaction conversion increased to about 25% (entries
4 and 5). When both T-Sav and catalyst 1 are included (1 : 1.2
ratio of catalyst to protein), the estimated conversion increased
to 77 and 95% at 1 and 2 mol% respectively (entries 6 and 7).
These results are in line with the findings that organocatalysis
is favored when executed in an environment that has low
dielectric constant, such as organic solvents and protein surface
or interior.19 Increasing the amount of BNAH to 5 equivalents in a
75 : 25 KPi : MeOH mixture enhances the conversion up to 94%
with only 1 mol% of T-Sav:1 (entry 8). Interestingly, when no
shaking was applied to the reaction mixture, the product conver-
sion decreases to 53% (entry 9). Lastly, in agreement with the
previous studies which illustrated that catalyst 2 is more flexible
and solvent-exposed when bound to T-Sav,20 the conversion was
lower when catalyst 2 was used (entry 10).
In most streptavidin-based artificial enzymes, the catalytic
centers are surrounded by residues at the intersubunit
interface.24,34 It however has recently been demonstrated that
such a shielded environment might not be ideal for some of
the chemical catalytic reactions; indeed, the monomeric variant
M-Sav can be a superior host to T-Sav for Rh-catalyzed
reactions.33 M-Sav was thus tested as an alternative host for
the organocatalytic transfer hydrogenation reaction. Neverthe-
less, in this case the conversion dropped to 21% and 10% by
catalyst 1 and 2 in M-Sav, respectively (entries 11 and 12). This
observation suggests that secondary amine-catalyzed transfer
hydrogenation prefers a more shielded protein scaffold. To see
how a change in hydride donor affects the conversion rate,
alternative hydride donors including Hantzsch ester (5) and
NADH (6) were tested, but their use resulted in significantly
lower conversion (entry 13 and 14). The negligible conversion
observed with NADH (5) could be caused by its structural
complexity, whereas the low solvent solubility of Hantzsch ester
(6) in aqueous buffer can influence its ability to transfer
hydride within the T-Sav scaffold.
Having the optimal conditions determined (Table 1, entry 8),
various aromatic a,b-unsaturated aldehydes were tested as
alternative substrates. The T-Sav:1 assembly showed significant
substrate promiscuity; cinnamaldehyde analogues with chloro,
fluoro or nitro substituent added at the para position can be
converted into the corresponding dihydro-products (Table 2),
while the background reactions remain negligible. Supported
by NMR analysis, modest conversion was also observed for the
methyl, bromo and methoxy analogues (60–76%). Together,
these observations suggest that the efficiency of hydride transfer
is largely affected by electrostatic properties of the substituents.
Kinetic properties of the streptavidin-based transfer hydrogena-
tion system were evaluated. The protein-based catalyst demon-
strates enzyme-like kinetic behaviours with catalytic efficiency
(kcat/KM
cinnamaldehyde) estimated to be 8.50  0.5 M1s1 at 25 1C
(Fig. 2). The corresponding kcat/KM for flavoprotein was reported to
Fig. 1 Combining the tetrameric streptavidin (T-Sav) with biotinylated
organocatalysts 1 or 2 to generate organocatalytic artificial enzymes
(T-Sav:1, PDB: 6GH7, 1.08 Å) for transfer hydrogenation reactions.









1 N.A. N.A. BNAH (4) N.A. 3
2 T-Sav N.A. BNAH (4) 1 5
3 M-Sav N.A. BNAH (4) 1 4
4 N.A. 1 BNAH (4) 1 26
5 N.A. 2 BNAH (4) 1 25
6 T-Sav 1 BNAH (4) 1 77
7 T-Sav 1 BNAH (4) 2 95
8 T-Sav 1 BNAH (4) 1 94d
9 T-Sav 1 BNAH (4) 1 53e, f
10 T-Sav 2 BNAH (4) 1 51
11 M-Sav 1 BNAH (4) 1 21
12 M-Sav 2 BNAH (4) 1 10
13 T-Sav 1 NADH (5) 1 5
14 T-Sav 1 Hantzsch (6) 1 0
a Estimated conversion was determined by the ratio of the corres-
ponding 1H NMR peak integration (see ESI). b Reactions performed in
a mixture 90 : 10 KPi 10 mM : MeOH at pH 7.0 using 1 equivalent of
aldehyde (6.6 mM) and 2 equivalents of 4 (13.2 mM). c In the absence of
catalyst, partial oxidation of BNAH was observed, but the oxidation rate
is negligible when compared to the protein-hosted organocatalytic
reaction. d Reactions performed in a mixture 75 : 25 KPi 10 mM : MeOH
at pH 7.0 using 1 equivalent of aldehyde (6.6 mM) and 5 equivalents of
4 (33 mM). e 0 rpm, side-product observed. f ppt observed. 1 mol% of
T-Sav/M-Sav corresponds to 66 nmol catalytic sites. N.A. indicates not
added.


























































































be 5900 M1s1. Furthermore, BNAH has been used for aromatic
hydroxylation and the reduction of the a,b-unsaturated carbonyl
substrate; their biomolecular reaction rate constants were measured
to be 1.2104 and 1.9106 M1s1, respectively.13,14 Although these
values are significantly higher than that of the streptavidin system,
the presented bottom-up approach has not yet been engineered and
offers significant flexibility in design.
QM/MM molecular dynamics (MD) simulations were con-
ducted to obtain a detailed understanding of the hydride
transfer step in the T-Sav:1 system. Exploration of the free
energy surface at M06-2X:RM1/MM level enabled identification
of the isolated structures of the reactants (in solution as
solvated species and in the active site of the protein scaffold
as the ‘‘Michaelis complex’’) and the hydride transfer transition
state (see ESI,† for details). Hence, the magnitude of the
[1,2-2H/1H] KIE was computationally assessed, including quan-
tum tunneling corrections required for chemical reactions
involving the transfer of a light particle such as hydride
transfer. The resulting KIE was found to be 3.89  0.15 when
the ground state of BNAH in aqueous solution was used, and
this parameter further increased to 4.28  0.18 when the
equilibrium between the Michaelis complex and the hydride
transfer transition state were used for calculation (see ESI,† for
details). These values are similar to those previously obtained
for hydride transfer processes catalyzed by NADH-dependent
enzymes,35,36 including L-lactate dehydrogenase (in the range
between 3.36 and 2.80)37 and morphinone reductase (8.4 1.6),38
but significantly higher than that of the experimental counterpart
measured in the present study. Interestingly, regarding the
hydride donor–acceptor distance and the relative orientation of
the different involved moieties, the nature of the optimized
transition state can be considered as equivalent to those located
in previous studies (Fig. 3).35–38 It therefore suggests that the
hydride transfer step in the T-Sav artificial enzyme is at least
partially rate-limiting.
In summary, we have described the use of streptavidin as a
host for organocatalytic transfer hydrogenations. At 1 mol%,
the T-Sav:1 assembly was able to mediate the hydrogenation of
various aromatic a,b-unsaturated aldehydes in excellent con-
versions, and the resulting products have been used in the
synthesis of pharmaceutical compounds.39 Moreover, T-Sav:1
possesses Michaelis Menten kinetic properties for the organo-
catalytic transfer hydrogenation, presenting as a great starting
point for artificial enzyme engineering. Studies focusing on the
reaction mechanisms, the use of prochiral aldehydes and
potential applications in cascade reactions are currently
ongoing.
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Table 2 Substrate scope for transfer hydrogenation from BNAH to aro-
matic a,b-unsaturated aldehydes mediated by T-Sav:1 assemblya









a Estimated conversion was determined by ratio of the corresponding
1H NMR peak integration (see ESI). b Reactions performed in a mixture
75 : 25 KPi 10 mM : MeOH at pH 7.0 using 1 equivalent of aldehyde
(6.6 mM) and 5 equivalents of 4 (33 mM) with 1 mol% of T-Sav:1.
c Reaction performed in a mixture of 9 : 1 KPi 10 mM : MeOH at pH
7.0 using 1 equivalent of aldehyde (6.6 mM) and 2 equivalents of 4
(13.2 mM). 1 mol% of T-Sav/M-Sav correspond to 66 nmol catalytic sites.
Fig. 2 Kinetic evaluation of the T-Sav:1 complex for transfer hydrogena-
tion from BNAH to cinnamaldehyde.
Fig. 3 Detail of the transition state for the hydride transfer from BNAH to
cinnamaldehyde in the active site of T-Sav:1 optimized at the M06-2X/MM
level. Average distances in Å.
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